Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
YTE-001 by Bristar Immunotech Biotechnology for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
YTE-001 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData,...
YT-19 by Bristar Immunotech Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
YT-19 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell...
CD19-STAR-T Cells by Bristar Immunotech Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19-STAR-T Cells is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL,...
YT-1920 by Bristar Immunotech Biotechnology for B-Cell Leukemia: Likelihood of Approval
YT-1920 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for B-Cell Leukemia. According to GlobalData,...
YT-1920 by Bristar Immunotech Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
YT-1920 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell...
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia by Bristar Immunotech Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia is under clinical development by...